A breast cancer study treats its first patient by freezing a tumor
IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.
How this was made
The 30-second read
Why it matters
The trial start provides a tangible milestone that can be used to gauge future commercial traction and revenue potential.
Market read
First‑patient enrollment signals progress toward commercial rollout, which may attract biotech investors seeking early‑stage device breakthroughs.
What to watch
Regulatory timelines, reimbursement landscape, and competition from alternative ablation technologies.
Background
Icecure Medical develops liquid‑nitrogen cryoablation systems; the ProSense® device is FDA‑cleared for low‑risk breast cancer in patients 70+.
Ticker impact
Icecure Medical announced the first patient was treated in its ChoICE Study, marking the start of patient enrollment for its ProSense® breast cancer cryoablation system.
likely upward pressure as investors price in future data and potential market expansion
Trial initiation is a material milestone for a biotech device company; positive perception can lift the stock ahead of forthcoming data.
Market effects
May boost interest in minimally invasive oncology devices and cryoablation technologies.
Primarily U.S. biotech and medical device markets.
Limited to investors tracking early-stage medical device pipelines.
Counterpoint
If early data are inconclusive, the stock could face disappointment and sell‑off.
Key entities
- CompanyIcecure Medical
NASDAQ‑listed developer of cryoablation devices.
- InstitutionWest Cancer Center & Research Institute
Clinical site where the first patient was treated.


